Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.

• DOI: 10.1200/jco.1996.14.9.2435
• Publication Date: 2017-02-23T13:12:31Z
• Authors: E Salloum; R Doria; W Schubert; D Zelterman; T Holford; K B Roberts; L R Farber; R K Kiehl; J Cardinale; D L Cooper
• Keywords: Latency stage

PURPOSE Late solid tumors (STs) are a significant cause of morbidity and mortality in long-term survivors Hodgkin's disease. To investigate the carcinogenic potential two different therapeutic approaches, we measured relative risk (RR) STs patients with early-stage disease cured after primary full-dose (approximately 40 Gy) radiation therapy (RT) advanced who were treated chemotherapy followed by low-dose (15 to 30 involved-field (CMT). PATIENTS AND METHODS Because therapy-induced generally begin latency period 5 10 years, restricted our analysis before 1986 achieved durable remissions. Patients required salvage or died excluded from analysis. The RR was calculated dividing observed number cases expected matched population Connecticut Tumor Registry. actuarial incidence also measured. RESULTS A total 197 formed RT group 116 CMT group. median follow-up 12.8 versus 13.5 years overall 1.5 (95% confidence interval [CI], 0.6 3.5; P = .122). There no lung breast cancer. In group, 3.3 CI, 2.0 5.3; < .001). seven cancer (RR 10.8; 95% 5.3 22.2; .001) 2; 7.4; .07). All six benign occurred CONCLUSION initial treatment for disease, associated statistically increase STs, particularly not STs. These data may have important implications design newer therapies